AtomVie Global Radiopharma

AtomVie is a startup operating in the healthcare sector, specifically in the production and supply of lutetium-177 (Lu-177), a radioisotope commonly used in targeted radiotherapy. The company has developed a new production technology for non-carrier added (n.c.a.) Lu-177, in collaboration with Isotopia, to ensure a stable and reliable supply. This technology has been successfully integrated into AtomVie's current Good Manufacturing Practice (GMP) facility, which is a system for ensuring that products are consistently produced and controlled according to quality standards.

AtomVie's primary clients are healthcare providers and institutions that require Lu-177 for radiotherapeutic treatments. The company operates in the global healthcare market, with a focus on meeting increasing supply demands in North America.

The business model of AtomVie is based on the production and distribution of Lu-177. The company generates revenue by selling this radioisotope to healthcare providers. AtomVie has already shipped its first doses of commercial n.c.a. Lu-177, indicating a successful start to its operations.

The company also places a strong emphasis on diversity and inclusivity, as evidenced by the testimonials of its employees. This not only creates a positive work environment but also contributes to the innovative and dynamic nature of the startup.

Keywords: Healthcare, Radiotherapy, Lutetium-177, Production, Supply, Collaboration, Isotopia, Good Manufacturing Practice, Diversity, Inclusivity.